The Swedish Department of Health announced today that it will postpone the Johnson & Johnson vaccine in the case of reports of rare blood clots similar to the AstraZeneca vaccine.
The health agency said in a statement that it will not start vaccinations and will wait for the European Medicines Agency (EMA)’s findings on the vaccine to be announced next week. Although the first 31,000 doses of vaccine have arrived in Sweden, the vaccine has not yet been vaccinated in Sweden.
After six recipients developed a rare disease involving blood clots, the US Federal Health Agency recommended that the Johnson & Johnson vaccine be suspended. Johnson & Johnson subsequently stated that it would postpone the introduction of the vaccine into Europe.
Leading epidemiologist Anders Tegnell (Anders Tegnell) said: “Before considering the Swedish proposal, we are seeking an analysis of the EMA and information from the United States. Prior to this, it is recommended not to use the vaccine dose. “
The health agency said it will not be able to make a prediction for the final decision. Denmark has also vaccinated Johnson & Johnson on ice, while France announced that it will vaccinate people over 55 years of age.